Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017233 | 0.91 | BCL2 (0.60) | BCL2PIK3CDNT5E | |
| SCHEMBL2163803 | 0.91 | BCL2 (0.60) | BCL2PIK3CDNT5E | |
| Cadaverine Tartrate SCHEMBL2163375 | 0.90 | BCL2 (0.53) | BCL2PIK3CDNT5EDPP4ADAMTS5 | |
| SCHEMBL2013843 | 0.84 | BCL2 (0.48) | BCL2PIK3CDNT5EADAMTS5PTPN11 | |
| SCHEMBL2019258 | 0.82 | PIK3CD (0.58) | BCL2PIK3CDNT5EADAMTS5L3MBTL1 | |
| SCHEMBL2163762 | 0.82 | PIK3CD (0.58) | BCL2PIK3CDNT5EADAMTS5L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL2013841 | 0.82 | BCL2 (0.42) | BCL2PIK3CDNT5EDPP4PTPN11 | |
| SCHEMBL12632222 | 0.82 | PIK3CD (0.59) | BCL2PIK3CDNT5EADAMTS5L3MBTL1 | |
| SCHEMBL2015596 | 0.81 | BCL2 (0.48) | BCL2PIK3CD | |
| Trifluoroacetic Acid SCHEMBL2012078 | 0.81 | BCL2 (0.41) | BCL2PIK3CDNT5EPTPN11GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | BCL2 1174/4885PIK3CD 13/4885NT5E 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.